English| Français| Nederlands| INDEX| CONTACT About Us | R&D | Products | News | Responsibility | Careers News Publications Press Releases Media Contacts Home » News » Press Releases Press Releases June 2017 - European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy May 2017 - European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Squamous Cell Cancer of the Head and Neck in Adults Progressing On or After Platinum-based Therapy March 2017 - Bristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer January 2017 - big leap in immunotherapy has finally arrived in Belgium : Opdivo is now reimbursed for four different types of cancer August 2016 - Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Please also read our press releases in French and Dutch Privacy Policy | Legal Notice | Pharmacovigilance | Contact This website has not been designed and must not be used to collect or provide safety information related to Bristol-Myers Squibb products. If your query relates to an adverse event experienced by a patient, please contact us on + 32/ 2.352.76.11 or e-mail: medicalinfo.belgium@bms.com ©2016 Bristol-Myers Squibb Belgium, Parc de l’Alliance, 4 Avenue de Finlande 1420 Braine l’Alleud. All company names and logos of BMS and / or the products of the company are trademarks of Bristol-Myers Squibb Company and / or affiliates, and are protected by national and international intellectual and industrial property laws. All rights to the contents of this website are reserved. Your use of this website is subject to the Legal Notice, the Privacy Policy, and the applicable laws and regulations.